REG - ValiRx PLC - Posting of Circular and Notice of General Meeting

ValiRxAnnouncement

Tue 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251104:nRSD1835Ga&default-theme=true

RNS Number : 1835G  ValiRx PLC  04 November 2025

4 November 2025

ValiRx PLC

("ValiRx" or the "Company")

Posting of Circular and Notice of General Meeting

 

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, announces that, further
to the announcement made on 30 October 2025, a circular (the "Circular"),
including the Notice of General Meeting and a Form of Proxy, has been posted
to shareholders.

 

The General Meeting will be held at the offices of Fieldfisher LLP, Riverbank
House, 2 Swan Lane, London, EC4R 3TT at 11 a.m. on 20 November 2025.

 

A copy of the Circular will shortly be available on the Company's website at
https://www.valirx.com/aim-rule-26 (https://www.valirx.com/aim-rule-26) .

 

Capitalised terms used in this announcement shall, unless otherwise defined,
have the same meanings as set out in the Company's announcement of 30 October
2025.

 

 

FUNDRAISING STATISTICS

 

 

 Issue Price                                                                  0.25 pence

 Number of Existing Shares                                                    374,348,672

 Number of Tranche 1 Placing Shares                                           112,304,600

 Number of Tranche 2 Placing Shares                                           183,695,400

 Aggregate Number of Placing Shares                                           296,000,000

 Number of WRAP Retail Offer Shares                                           60,722,400

 Number of Subscription Shares                                                4,000,000

 Number of Fee Shares                                                         7,650,000

 Aggregate Number of New Ordinary Shares to be issued in connection with the  368,372,400
 Fundraising

 Number of Shares in issue following Admission and issue of the New Ordinary  742,721,072
 Shares

 Percentage of the Enlarged Share Capital represented by the New Ordinary     49.60%
 Shares

 Number of Fundraising Warrants to be issued following Admission               368,372,400
 Number of Broker Warrants to be issued following Admission                    16,036,120
 Gross proceeds of the Placing                                                £740,000

 Gross proceeds of the WRAP Retail Offer                                      £152,000

 Gross proceeds of the Subscription                                           £10,000

 Gross proceeds of the Fundraising                                            £902,000

 Ordinary Share ISIN                                                          GB00BLH13C52

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

 

 

                                                                                 2025

 Announcement of the Fundraising                                                 30 October

 Launch of the WRAP Retail Offer                                                 30 October

 Date of publication and posting of this Circular & the Form of Proxy            4 November

 Announcement of the results of the WRAP Retail Offer                            4 November

 Admission and dealings in the Tranche 1 Placing Shares expected to commence on  8:00 a.m. on or around 6 November
 AIM

 Expected date for CREST accounts to be credited for Tranche 1 Placing Shares    6 November
 to be held in uncertificated form

 Despatch of definitive share certificates in respect of the Tranche 1 Placing   by 20 November
 Shares to be held in certificated form, if applicable

 Latest time and date for receipt of CREST Proxy Votes or the completed Forms    11.00 a.m. on 18 November
 of Proxy

 General Meeting                                                                 11.00 a.m. on 20 November

 Announcement of the results of the General Meeting                              20 November

 Admission and dealings in the Tranche 2 Placing Shares, Subscription Shares,    8:00 a.m. on or around 21 November
 Fee Shares and WRAP Retail Offer Shares expected to commence on AIM

 Expected date for CREST accounts to be credited for Tranche 2 Placing Shares,   21 November
 Subscription Shares, WRAP Retail Offer Shares, Fee Shares and Fundraising
 Warrants to be held in uncertificated form

 Despatch of definitive share certificates in respect of the Tranche 2 Placing   by 5 December
 Shares, Subscription Shares, WRAP Retail Offer Shares, Fee Shares and
 Fundraising Warrants to be held in certificated form, if applicable

 

Notes:

 

1. Each of the times and dates above are indicative only and if any of the
details contained in the timetable above should change, the revised times and
dates will be notified to Shareholders by means of an announcement through a
Regulatory Information Service.

 

2. All of the above times refer to London time unless otherwise stated.

 

3. All events listed in the above timetable related to the granting of the
Fundraising Warrants and the Broker Warrants and Admission of the Tranche 2
Placing Shares, the Subscription Shares, the WRAP Retail Offer Shares and the
Fee Shares are conditional on the passing at the General Meeting of the
Fundraising Resolutions to provide the relevant authorities.

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

For more information, please contact:

 Investor questions on this announcement           https://valirx.com/link/yVwkje

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti
 Shard Capital Partners LLP (Broker)               Tel: +44 (0) 20 7186 9000

 Damon Heath

 Andrew Gutmann
 SP Angel Corporate Finance LLP (Placing Agent)    Tel: +44 (0) 20 3470 0470

 David Hignell

 Vadim Alexandre
 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive                lucy@vformation.biz

 Sue Carr - Director                               sue@vformation.biz

 

Background to and Reasons for the Fundraising

 

ValiRx is an AIM-quoted life science company focused on cancer therapeutics
and women's health. The Company seeks to identify the most promising research
in academia and innovative biotechnology companies and translate this research
towards clinical development, providing a pathway to commercialisation.

 

The Company has identified certain fundamental issues impacting drug
development today, in terms of innovation, productivity and access. A lack of
expertise in early-stage drug developers, particularly in academia,
contributes to low rates of success in translating novel scientific research
into valuable new therapeutic assets, hindering both the adoption of
innovation and the overall productivity of developing new treatments.

 

To address these fundamental issues, ValiRx has adopted a strategy to improve
the efficacy of translating promising novel research into the preclinical
development phase, with a particular focus on women's health and oncology.
Combining its clinical knowledge, deep biological expertise, data generation
and data interpretation abilities, ValiRx seeks to unlock the substantial
potential of early-stage innovation and provide a specialist service for its
in-house collaborative projects and third-party innovators through its
subsidiary, Inaphaea Biolabs Limited ("Inaphaea").

 

Use of Proceeds

 

The proceeds of the Fundraising, in aggregate of approximately £902,000
(before expenses), are intended to be used by the Group for the following:

 

                                                                              Estimated cost
 ·      R&D: invest into the ValiRx future collaborative pipeline             £0.4m
 ·      R&D: preclinical development of Cytolytix                             £0.2m
 ·      R&D: preclinical development of VAL201 2.0                            £0.05m
 ·      Operating costs (balance from R&D tax credits, revenue and            £0.25m
 grants)

 

For the purposes of section 571(6)(c) of the Companies Act 2006, the Issue
Price has been determined by the Company following discussions with market
participants and its professional advisers.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGEAXFLEFDSFFA



            Copyright 2019 Regulatory News Service, all rights reserved